NL9102071A - Geneesmiddelen. - Google Patents
Geneesmiddelen. Download PDFInfo
- Publication number
- NL9102071A NL9102071A NL9102071A NL9102071A NL9102071A NL 9102071 A NL9102071 A NL 9102071A NL 9102071 A NL9102071 A NL 9102071A NL 9102071 A NL9102071 A NL 9102071A NL 9102071 A NL9102071 A NL 9102071A
- Authority
- NL
- Netherlands
- Prior art keywords
- indole
- ethyl
- methyl
- dimethylamino
- methanesulfonamide
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 12
- 239000000243 solution Substances 0.000 claims description 53
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000012453 solvate Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- GIYWWORAURQCTI-UHFFFAOYSA-N 1-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]-n-methylmethanesulfonamide;sulfuric acid Chemical compound OS(O)(=O)=O.CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 GIYWWORAURQCTI-UHFFFAOYSA-N 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 13
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 11
- 208000019695 Migraine disease Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 206010027599 migraine Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 238000009472 formulation Methods 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 6
- 229960000686 benzalkonium chloride Drugs 0.000 description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
- 229940067107 phenylethyl alcohol Drugs 0.000 description 5
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 229940081974 saccharin Drugs 0.000 description 3
- 235000019204 saccharin Nutrition 0.000 description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical class C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 206010009094 Chronic paroxysmal hemicrania Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- WYFWKMQPMCPKLZ-UHFFFAOYSA-N n,n-dimethyl-2-(1-methylindol-3-yl)ethanamine Chemical compound C1=CC=C2C(CCN(C)C)=CN(C)C2=C1 WYFWKMQPMCPKLZ-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000007777 paroxysmal Hemicrania Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9026998 | 1990-12-12 | ||
| GB909026998A GB9026998D0 (en) | 1990-12-12 | 1990-12-12 | Medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL9102071A true NL9102071A (nl) | 1992-07-01 |
Family
ID=10686904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL9102071A NL9102071A (nl) | 1990-12-12 | 1991-12-11 | Geneesmiddelen. |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US5554639A (cs) |
| EP (1) | EP0490689B1 (cs) |
| JP (1) | JP2994037B2 (cs) |
| KR (1) | KR100211479B1 (cs) |
| CN (2) | CN1030890C (cs) |
| AP (1) | AP230A (cs) |
| AT (1) | ATE119881T1 (cs) |
| AU (1) | AU650706B2 (cs) |
| BE (1) | BE1005085A3 (cs) |
| CA (1) | CA2098302C (cs) |
| CH (1) | CH684192A5 (cs) |
| CY (1) | CY2005A (cs) |
| CZ (1) | CZ281931B6 (cs) |
| DE (1) | DE69108200T2 (cs) |
| DK (1) | DK0490689T3 (cs) |
| EG (1) | EG20219A (cs) |
| ES (1) | ES2069836T3 (cs) |
| FR (1) | FR2670487B1 (cs) |
| GB (2) | GB9026998D0 (cs) |
| GR (1) | GR3015430T3 (cs) |
| HK (1) | HK82697A (cs) |
| HU (1) | HU211937A9 (cs) |
| IE (1) | IE62894B1 (cs) |
| IL (1) | IL100330A (cs) |
| IS (1) | IS1706B (cs) |
| IT (1) | IT1252868B (cs) |
| MX (1) | MX9102501A (cs) |
| MY (1) | MY109265A (cs) |
| NL (1) | NL9102071A (cs) |
| NZ (1) | NZ240942A (cs) |
| PT (1) | PT99757B (cs) |
| RU (1) | RU2108328C1 (cs) |
| TW (2) | TW300886B (cs) |
| WO (1) | WO1992010477A1 (cs) |
| YU (1) | YU48926B (cs) |
| ZA (1) | ZA919750B (cs) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA27908C2 (uk) * | 1992-06-05 | 2000-10-16 | Мерк Шарп Енд Дом Лімітед | Сульфатна сіль n,n-диметил-2-[5-(1,2,4-триазол-1ілметил)-1н-індол-3-іл]етиламіну та/або її сольвати, фармацевтична композиція на її основі, спосіб одержання фармацевтичної композиції і спосіб лікування |
| FR2749846B1 (fr) * | 1996-06-17 | 1998-09-11 | Pf Medicament | Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique |
| US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US6106837A (en) * | 1997-05-15 | 2000-08-22 | Hirsch; Alan R. | Method of treating headaches, and article of manufacture therefor |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
| US6132757A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| US6187790B1 (en) | 1999-03-04 | 2001-02-13 | Neal R. Cutler | Use of cilostazol for treatment of sexual dysfunction |
| US6426084B1 (en) * | 2000-06-19 | 2002-07-30 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| GB9926250D0 (en) * | 1999-11-06 | 2000-01-12 | Knoll Ag | Chemical process |
| US6610271B2 (en) * | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
| US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
| US6458804B1 (en) | 2001-01-26 | 2002-10-01 | R.T. Alamo Venturesi, Llc | Methods for the treatment of central nervous system disorders in certain patient groups |
| US6562838B2 (en) | 2001-01-26 | 2003-05-13 | R. T. Alamo Ventures I, L.L.C. | Treatment of cardiovascular disease with quinolinone enantiomers |
| US6451813B1 (en) | 2001-01-26 | 2002-09-17 | R. T. Alamo Ventures I, Llc | Treatment of gastroparesis in certain patient groups |
| US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| US20030096748A1 (en) * | 2001-06-04 | 2003-05-22 | The Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
| US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| DE60228294D1 (en) * | 2001-06-05 | 2008-09-25 | Ronald Aung-Din | Topische migränetherapie |
| US7041677B2 (en) * | 2002-03-01 | 2006-05-09 | R.T. Alamo Ventures I, Llc | Use of monochloroflosequinan in the treatment of sexual dysfunction |
| US7208628B2 (en) * | 2002-05-13 | 2007-04-24 | Kansas State University Research Foundation | Compositions and methods for the treatment of hepatitis C virus infection |
| US7074893B2 (en) * | 2002-06-03 | 2006-07-11 | Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
| US20040068000A1 (en) * | 2002-10-02 | 2004-04-08 | Mintong Guo | Compression coated tablets |
| WO2004060355A1 (en) * | 2002-12-26 | 2004-07-22 | Pozen Inc. | Multilayer Dosage Forms Containing NSAIDs and Triptans |
| US20080213363A1 (en) * | 2003-01-23 | 2008-09-04 | Singh Nikhilesh N | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa |
| WO2004076403A1 (en) * | 2003-02-24 | 2004-09-10 | Transform Pharmaceuticals, Inc. | Sumatriptan crystalline forms, pharmaceutical compositions and methods |
| US20070065463A1 (en) | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| US20050089558A1 (en) * | 2003-10-28 | 2005-04-28 | Alamo Pharmaceuticals, Llc | Compositions and methods for the co-formulation and administration of tramadol and propoxyphene |
| WO2005119607A2 (en) * | 2004-06-03 | 2005-12-15 | Tyfone, Inc. | System and method for securing financial transactions |
| EP1765300A2 (en) * | 2004-06-10 | 2007-03-28 | Duramed Pharmaceuticals, Inc. | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| CN101754947A (zh) | 2005-05-20 | 2010-06-23 | 詹森药业有限公司 | 磺酰胺衍生物的制备方法 |
| WO2007070504A2 (en) * | 2005-12-13 | 2007-06-21 | Morton Grove Pharmaceuticals, Inc. | Stable and palatable oral liquid sumatriptan compositions |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US20070191461A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine |
| US8853263B2 (en) | 2006-05-19 | 2014-10-07 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
| US8653066B2 (en) | 2006-10-09 | 2014-02-18 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| AU2007310949A1 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| US20080275030A1 (en) * | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| GB2448183A (en) * | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
| JP5714910B2 (ja) | 2008-01-09 | 2015-05-07 | チャールストン ラボラトリーズ，インコーポレイテッド | 薬学的組成物 |
| US20090252791A1 (en) * | 2008-04-02 | 2009-10-08 | Venkata Nookaraju Sreedharala | Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug |
| KR20110019759A (ko) | 2008-05-27 | 2011-02-28 | 비오타 사이언티픽 매니지먼트 피티와이 엘티디 | 항바이러스 염 |
| CN102088966B (zh) * | 2008-06-20 | 2015-06-10 | 阿尔法制药有限公司 | 药物制剂 |
| BRPI0915890A2 (pt) | 2008-06-23 | 2015-11-03 | Janssen Pharmaceutica Nv | forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida |
| CA2729346A1 (en) * | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| EP3311667A1 (en) | 2009-07-08 | 2018-04-25 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| US11337962B2 (en) | 2009-09-25 | 2022-05-24 | Upsher-Smith Laboratories, Llc | Formulations comprising triptan compounds |
| DK2480197T3 (en) | 2009-09-25 | 2016-01-25 | Reddys Lab Ltd Dr | Compositions containing triptanforbindelser |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| BR112017018944A2 (pt) | 2015-03-02 | 2018-05-15 | Afgin Pharma Llc | método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) |
| WO2016187013A1 (en) | 2015-05-15 | 2016-11-24 | The Regents Of The University Of Michigan | Methods and compositions for the treatment of arthritis |
| WO2017152130A1 (en) | 2016-03-04 | 2017-09-08 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
| US10723718B2 (en) | 2017-11-07 | 2020-07-28 | The Regents Of The University Of Michigan | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use |
| US20220096438A1 (en) | 2018-09-07 | 2022-03-31 | Upsher-Smith Laboratories, Llc | Methods of treating migraine |
| US11364225B2 (en) * | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
| BR112022016790A2 (pt) * | 2020-02-27 | 2022-11-08 | Biohaven Pharm Holding Co Ltd | Forma de dosagem oral de dispersão rápida de rimegepant |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2162522B (en) * | 1984-08-01 | 1988-02-24 | Glaxo Group Ltd | An indole derivative |
| GB8615599D0 (en) * | 1986-06-26 | 1986-07-30 | Glaxo Group Ltd | Chemical compounds |
| GB8928208D0 (en) * | 1989-12-13 | 1990-02-14 | Glaxo Group Ltd | Medicaments |
-
1990
- 1990-12-12 GB GB909026998A patent/GB9026998D0/en active Pending
-
1991
- 1991-12-10 JP JP4501645A patent/JP2994037B2/ja not_active Expired - Lifetime
- 1991-12-10 CA CA002098302A patent/CA2098302C/en not_active Expired - Lifetime
- 1991-12-10 WO PCT/EP1991/002362 patent/WO1992010477A1/en not_active Ceased
- 1991-12-10 YU YU191491A patent/YU48926B/sh unknown
- 1991-12-10 KR KR1019930701760A patent/KR100211479B1/ko not_active Expired - Fee Related
- 1991-12-10 CZ CS931140A patent/CZ281931B6/cs not_active IP Right Cessation
- 1991-12-10 RU RU93053493A patent/RU2108328C1/ru not_active IP Right Cessation
- 1991-12-10 AU AU90720/91A patent/AU650706B2/en not_active Expired
- 1991-12-11 PT PT99757A patent/PT99757B/pt not_active IP Right Cessation
- 1991-12-11 BE BE9101129A patent/BE1005085A3/fr not_active IP Right Cessation
- 1991-12-11 AP APAP/P/1991/000339A patent/AP230A/en active
- 1991-12-11 IE IE431791A patent/IE62894B1/en not_active IP Right Cessation
- 1991-12-11 TW TW081105493A patent/TW300886B/zh active
- 1991-12-11 GB GB9126297A patent/GB2251614B/en not_active Revoked
- 1991-12-11 IT ITRM910922A patent/IT1252868B/it active IP Right Grant
- 1991-12-11 NZ NZ240942A patent/NZ240942A/en not_active IP Right Cessation
- 1991-12-11 IL IL10033091A patent/IL100330A/en not_active IP Right Cessation
- 1991-12-11 NL NL9102071A patent/NL9102071A/nl not_active Application Discontinuation
- 1991-12-11 TW TW080109719A patent/TW205035B/zh not_active IP Right Cessation
- 1991-12-11 MX MX9102501A patent/MX9102501A/es unknown
- 1991-12-11 ZA ZA919750A patent/ZA919750B/xx unknown
- 1991-12-11 IS IS3790A patent/IS1706B/is unknown
- 1991-12-11 EG EG75391A patent/EG20219A/xx active
- 1991-12-11 CH CH3647/91A patent/CH684192A5/fr not_active IP Right Cessation
- 1991-12-11 CN CN91107596A patent/CN1030890C/zh not_active Expired - Fee Related
- 1991-12-11 MY MYPI91002297A patent/MY109265A/en unknown
- 1991-12-11 FR FR919115359A patent/FR2670487B1/fr not_active Expired - Lifetime
- 1991-12-12 AT AT91311583T patent/ATE119881T1/de not_active IP Right Cessation
- 1991-12-12 DK DK91311583.8T patent/DK0490689T3/da active
- 1991-12-12 DE DE69108200T patent/DE69108200T2/de not_active Expired - Lifetime
- 1991-12-12 EP EP91311583A patent/EP0490689B1/en not_active Expired - Lifetime
- 1991-12-12 ES ES91311583T patent/ES2069836T3/es not_active Expired - Lifetime
-
1995
- 1995-02-20 CN CN95100529A patent/CN1050831C/zh not_active Expired - Fee Related
- 1995-03-16 GR GR940403944T patent/GR3015430T3/el unknown
- 1995-06-02 US US08/460,791 patent/US5554639A/en not_active Expired - Lifetime
- 1995-06-23 HU HU95P/P00422P patent/HU211937A9/hu unknown
-
1996
- 1996-05-21 US US08/651,961 patent/US5705520A/en not_active Expired - Lifetime
-
1997
- 1997-06-19 HK HK82697A patent/HK82697A/en not_active IP Right Cessation
- 1997-12-05 CY CY200597A patent/CY2005A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL9102071A (nl) | Geneesmiddelen. | |
| RU2762725C2 (ru) | Композиции, содержащие триптановые соединения | |
| US5393773A (en) | Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide | |
| JPH01153639A (ja) | 鼻又は目に使用する薬剤及びその製造法 | |
| CA2392050C (en) | Pharmaceutical formulations containing zolmitriptan | |
| RU2130022C1 (ru) | N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство | |
| RU2242231C2 (ru) | Парентеральная композиция для лечения эпилепсии | |
| KR100384346B1 (ko) | 엘레트립탄 헤미술페이트 및 카페인을 포함하는 약제학적조성물 | |
| RU2710372C2 (ru) | Композиции, содержащие триптановые соединения | |
| CN107921023A (zh) | 用于治疗偏头痛的包含舒马曲坦的药物组合物 | |
| NO179102B (no) | 3-[2-(dimetylamino)etylÅ-N-metyl-1H-indol-5-metansulfonamid | |
| JP2011173801A (ja) | ケトチフェン配合水性組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BV | The patent application has lapsed |